Halozyme Therapeutics

HALONasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$12.231 B

$103.12 +20.24%

Close of 7 Aug 2026

Revenue

$1.40B

#1342 by revenue

Earnings

$316.9M

#814 by earnings

Shares outstanding

113,498,000

Latest filing cover page

P/E ratio

38.6

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#8Neurocrine BiosciencesNBIX$16.6B
#9ExelixisEXEL$13.4B
#10Halozyme TherapeuticsHALO$12.2B
#11Bio-TechneTECH$11.3B
#12Apogee TherapeuticsAPGE$10.2B

Where these numbers come from

Share counts and financials for Halozyme Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.